Basel, Switzerland, February 2026 — Sami Atiya has been nominated to join the Board of Directors of Lonza, subject to his election at the Annual General Meeting (AGM) in May 2026. Upon election, he will also serve on the Board’s Strategy and Innovation Committee.
Lonza, a global pioneer and leader in the CDMO industry, plays a critical role in advancing cutting-edge science and enabling the manufacture of life-saving medicines. Sami’s nomination reflects the company’s continued focus on innovation, technology, and long-term strategic growth. With deep experience across healthcare, robotics, automation, and artificial intelligence, he is expected to contribute significantly to Lonza’s strategy of “Making the Medicines of Tomorrow.”
Sami currently serves as President of the Robotics & Discrete Automation business at ABB and is a Member of the Group Executive Committee. Since 2019, he has led ABB’s robotics and automation portfolio, driving innovation in AI-enabled robotics, autonomous mobile robots, and next-generation automation platforms. Under his leadership, ABB expanded its AI navigation capabilities through the acquisition of Sevensense and strengthened its robotics platform innovation with initiatives such as OmniCore™.
Prior to ABB, Sami held senior leadership roles at Siemens, including CEO of the Mobility and Logistics Division and CEO of the Computer Tomography division at Siemens Healthcare. His career at Siemens spanned more than a decade and included executive positions across healthcare technology, medical imaging, and enterprise transformation. Earlier in his career, he held leadership and consulting roles at Robert Bosch, Fraunhofer-Gesellschaft, and other technology-focused organizations, building a strong foundation in robotics, artificial intelligence, and industrial innovation.
With decades of experience at the intersection of advanced technology and healthcare innovation, Sami Atiya brings a strong strategic perspective to Lonza as it continues to expand its role as a leading global CDMO.
About Lonza
Lonza is a pioneer and world leader in the Contract Development and Manufacturing Organization (CDMO) industry. Founded in Switzerland in 1897, the company supports pharmaceutical and biotech innovators by turning breakthrough science into viable therapies and manufacturing medicines at scale. With approximately 18,500 colleagues worldwide, Lonza delivers integrated solutions across five continents to bring life-enhancing and life-saving treatments to patients globally.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
